This new molecular test would revolutionize the pharmaceutical and renal dialysis services industry to provide positive health outcomes on a worldwide scale, particularly when considering 250 million people have diabetes globally. Pharmaceutical companies could use this test in conjunction with drug development to identify which patients the drug would work for and therefore the test would be involved in curing the disease and potential other related and unrelated diseases. I have attracted a large international partner that is working with us to move this test forward. It is and continues to be exciting.
Dr Richard Lipscombe
Importantly, the methods used to discover the biomarkers can be used for other illnesses and diseases in children and adults such as Type 1 Diabetes, cancers, Alzheimer’ s and much much more to potentially effect health outcomes that would be legendary in any measure.
My enthusiasm for this technology that represents the frontier of life sciences is overwhelming, however our challenge is to generate sufficient funding to apply this world medical breakthrough know how for other diseases. Interestingly, the highly conservative pharmaceutical industry has recently transformed itself towards the development of molecular diagnostic tests that help identify which patients medications would work for. Several new drugs have been quickly developed at less cost than other drugs because of this ability to stratify patients and know which ones the drug will work, or not or have side effects, etc. The issue is that the behemoth pharmaceutical industry is primarily focused in the science of genes, which compared to proteomics and other such‘ omics’ is low tech.
Nonetheless, the field of proteomics is now starting to become known for several reasons in addition to what I have already mentioned and represent other exciting areas that we are working in that is at the forefront of the industry.
The concept of a generic is familiar to most, however there are a separate class of medicines that have been derived from biological origins( biogenerics). Once a drug comes off of its patent that has protected it from competitors for years, proteomics analysis is used by a company to help develop their biogeneric medication. This is cool but we only provide an analytical service and although it is cutting edge, it is relatively routine.
The other interesting work our company does is with venom of highly poisonous Australian scorpions, spiders and centipedes to help discover new medicines that would be used to treat pain or kill microbes. Australia has been used previously to develop these types of biological medicines as one company used the cone shell to extract its highly toxic venom. Our drug discovery platform has the ability to provide much needed molecules to the pharmaceutical industry who would then develop these drugs and this is very exciting. Of course more funding is needed for this which we are chasing up. The guy at the helm is a brilliant protein chemist from Oxford University- Dr Richard Lipscombe. Working with him on a daily basis is energizing and inspiring even though he is a typical Brit as he drinks his white tea and continually corrects my American English! Many times we would have skype meetings or teleconferences from his home office due to the vast time zone differences. In his home office he has a few spiders that have nested in the window- so I call him the Spider Man. We have some major advancements nts at the company of late that I have been instrumental in arranging that I hope will set the company up for substantial future growth.
BARRY STEVEN EPSTEIN- PhotoAutobiography DRAFT 143 of 156